{"id":3348,"date":"2024-01-04T11:32:33","date_gmt":"2024-01-04T10:32:33","guid":{"rendered":"https:\/\/www.ptc.cz\/co-liecime\/prostata\/jak-poznat-rakovinu-prostaty\/vysledky-prazskeho-protonoveho-centra\/"},"modified":"2024-06-12T10:24:57","modified_gmt":"2024-06-12T08:24:57","slug":"vysledky-prazskeho-protonoveho-centra","status":"publish","type":"page","link":"https:\/\/www.ptc.cz\/sk\/co-liecime\/prostata\/jak-poznat-rakovinu-prostaty\/vysledky-prazskeho-protonoveho-centra\/","title":{"rendered":"V\u00fdsledky pra\u017esk\u00e9ho Prot\u00f3nov\u00e9ho centra"},"content":{"rendered":"
\n
\n
\n

Dlhodob\u00e9 v\u00fdsledky lie\u010dby karcin\u00f3mu prostaty v Protonovom centre v Prahe publikovali dva prest\u00ed\u017ene medic\u00ednske \u010dasopisy.<\/strong><\/p>\n

Ultra-hypofrakcionov\u00e1 prot\u00f3nov\u00e1 r\u00e1dioterapia v lie\u010dbe stredne a n\u00edzkorizikov\u00fdch n\u00e1dorov prostaty \u2013 v\u00fdsledky za obdobie 5 rokov od ukon\u010denia lie\u010dby.<\/p>\n

Jednou z prv\u00fdch pr\u00e1c, ktor\u00e1 na z\u00e1klade d\u00e1t o lie\u010dbe pacientov v PTC vy\u0161la v polovici febru\u00e1ra roku 2021.<\/p>\n

\u0160t\u00fadiu publikoval prest\u00ed\u017eny zahrani\u010dn\u00fd \u010dasopis pre radia\u010dn\u00fa onkol\u00f3giu International Journal of Radiation Oncology, Biology and Physics a sledovalo v priebehu 8 rokov celkom 279 pacientov, ktor\u00ed sa lie\u010dili s karcin\u00f3mom prostaty pomocou prot\u00f3novej r\u00e1dioterapie met\u00f3dou ceruzkov\u00e9ho skenovania (v priemere lie\u010dba trvala 9 dn\u00ed). Priniesla zauj\u00edmav\u00e9 v\u00fdsledky. \u201eTie ukazuj\u00fa, \u017ee 5 rokov po lie\u010dbe je 97 % pacientov s n\u00edzko rizikov\u00fdm karcin\u00f3mom prostaty vylie\u010den\u00fdch a nedo\u0161lo u nich k zv\u00fd\u0161eniu PSA (\u010di\u017ee prostatick\u00e9ho antig\u00e9nu). U pacientov s karcin\u00f3mom prostaty stredn\u00e9ho rizika m\u00f4\u017eeme kon\u0161tatova\u0165, \u017ee ich bolo vylie\u010den\u00fdch celkom 90 %,\u201c uv\u00e1dza doc. MUDr. Ji\u0159\u00ed Kube\u0161, Ph.D. V sledovanom s\u00fabore pacientov navy\u0161e nikto z pacientov na karcin\u00f3m prostaty nezomrel a v\u0161etci pacienti mali len minim\u00e1lne ne\u017eiaduce \u00fa\u010dinky (tzv. toxicitu).<\/p>\n

\"\"<\/p>\n<\/div>\n<\/div>\n

\n
\n

Po publik\u00e1cii tejto \u0161t\u00fadie t\u00edm lek\u00e1rov Protonov\u00e9ho centra vo svojom lie\u010debnom a publika\u010dnom \u00fasil\u00ed \u010falej pokra\u010doval a v\u00fdsledkom je druh\u00e1, retrospekt\u00edvna anal\u00fdza, ktorej hlavn\u00fdm \u00fa\u010delom bolo potvrdi\u0165 v\u00fdsledky prvej \u0161t\u00fadie.<\/p>\n

P\u00e4\u0165ro\u010dn\u00e1 anal\u00fdza \u00fa\u010dinnosti a toxicity ultra-hypofrakcionovanej prot\u00f3novej r\u00e1dioterapie pri lie\u010dbe karcin\u00f3mu prostaty s n\u00edzkym a stredn\u00fdm rizikom – retrospekt\u00edvna anal\u00fdza<\/strong><\/em><\/p>\n

Vy\u0161la v roku 2023 v recenzovanom lek\u00e1rskom \u010dasopise Cancers. \u201eU\u017e pred publik\u00e1ciou na\u0161ej prvej pr\u00e1ce v\u0161eobecne sch\u00e1dzali cenn\u00e9 d\u00e1ta z lie\u010dby v\u00e4\u010d\u0161ieho s\u00faboru pacientov. Preto je na\u0161a druh\u00e1 anal\u00fdza ak\u00fdmsi roz\u0161\u00edren\u00edm sk\u00f4r publikovan\u00fdch v\u00fdsledkov, ktor\u00e9 sme zverejnili na z\u00e1klade pozorovania men\u0161ieho po\u010dtu pacientov. Na\u0161\u00edm cie\u013eom bolo tentoraz overi\u0165 v\u00fdsledky prot\u00f3novej lie\u010dby pri karcin\u00f3me prostaty na dostato\u010dne ve\u013ekom s\u00fabore pacientov, ktor\u00ed lie\u010dbu prot\u00f3nmi podst\u00fapili,\u201c vysvet\u013euje d\u00f4vody pre vznik druhej anal\u00fdzy docent Kube\u0161.<\/p>\n

Po\u010das minim\u00e1lneho 6-mesa\u010dn\u00e9ho post o\u017earovacieho sledovania odlie\u010den\u00ed pacienti podstupovali klinick\u00e9 vy\u0161etrenia, meranie PSA a vyhodnocovanie pr\u00edpadn\u00fdch ved\u013eaj\u0161\u00edch \u00fa\u010dinkov lie\u010dby (tzv. toxicitu). \u201eAj v\u00fdsledky druhej \u0161t\u00fadie n\u00e1m potvrdili takmer 97% \u00faspe\u0161nos\u0165 vylie\u010denia ochorenia u pacientov s n\u00edzkorizikov\u00fdm ochoren\u00edm. Biochemick\u00fd n\u00e1vrat ochorenia sme zaznamenali iba u 58 pacientov, \u010do predstavuje 6,8 % z celkov\u00e9ho po\u010dtu 853 sledovan\u00fdch pacientov. 94,1 % pacientov z cel\u00e9ho sledovan\u00e9ho s\u00faboru bolo v 5-ro\u010dnom sledovacom obdob\u00ed bez biochemickej recid\u00edvy ochorenia, komentuje z\u00e1very potvrdzovacej anal\u00fdzy prim\u00e1r Kube\u0161.<\/p>\n

\"\"<\/p>\n<\/div>\n<\/div>\n<\/div>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

 <\/p>\n","protected":false},"author":1,"featured_media":3038,"parent":3343,"menu_order":485,"comment_status":"closed","ping_status":"closed","template":"template-service-detail-with-sidebar.php","meta":{"footnotes":""},"class_list":["post-3348","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.ptc.cz\/sk\/wp-json\/wp\/v2\/pages\/3348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ptc.cz\/sk\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ptc.cz\/sk\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ptc.cz\/sk\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ptc.cz\/sk\/wp-json\/wp\/v2\/comments?post=3348"}],"version-history":[{"count":3,"href":"https:\/\/www.ptc.cz\/sk\/wp-json\/wp\/v2\/pages\/3348\/revisions"}],"predecessor-version":[{"id":3525,"href":"https:\/\/www.ptc.cz\/sk\/wp-json\/wp\/v2\/pages\/3348\/revisions\/3525"}],"up":[{"embeddable":true,"href":"https:\/\/www.ptc.cz\/sk\/wp-json\/wp\/v2\/pages\/3343"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ptc.cz\/sk\/wp-json\/wp\/v2\/media\/3038"}],"wp:attachment":[{"href":"https:\/\/www.ptc.cz\/sk\/wp-json\/wp\/v2\/media?parent=3348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}